## Mps1-IN-3 hydrochloride

Cat. No.:	HY-12401A	
Molecular Formula:	C <sub>26</sub> H <sub>32</sub> ClN <sub>7</sub> O <sub>4</sub> S	
Molecular Weight:	574.09	HO
Target:	Mps1	
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton	
Storage:	-20°C, sealed storage, away from moisture	V N N H
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	H-CI

## SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 20 mg/mL (34.84 mM)

\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.7419 mL	8.7094 mL	17.4189 mL
	5 mM	0.3484 mL	1.7419 mL	3.4838 mL
	10 mM	0.1742 mL	0.8709 mL	1.7419 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY		
Description	Mps1-IN-3 hydrochloride is a potent and selective Mps1 inhibitor with an IC <sub>50</sub> value of 50 nM. Mps1-IN-3 hydrochloride can inhibit the proliferation of glioblastoma cells, and effectively sensitizes glioblastomas to Vincristine in orthotopic glioblastoma xenograft model <sup>[1]</sup> .	
IC <sub>50</sub> & Target	IC <sub>50</sub> : 50 nM (Mps1) <sup>[1]</sup>	
In Vitro	Mps1-IN-3 hydrochloride (0.3-10 μM) inhibits the marker of mitotic cells cyclin B in a dose-dependent manner <sup>[1]</sup> . Mps1-IN-3 hydrochloride (2 μM) causes a dose-dependent escape from a checkpoint-mediated mitotic arrest <sup>[1]</sup> . Mps1-IN-3 hydrochloride (1-15 μM) inhibits the proliferation of U251 glioblastoma cells with an IC <sub>50</sub> value of ~5 μM <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Mps1-IN-3 hydrochloride (2 mg/kg; IV, twice a week, for 3 weeks) effectively sensitizes glioblastomas to Vincristine in orthotopic glioblastoma xenograft models <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	



• Cell Metab. 2021 Jun 1;33(6):1111-1123.e4.

See more customer validations on www.MedChemExpress.com

## REFERENCES

[1]. Tannous BA, et al. Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs. J Natl Cancer Inst. 2013 Sep 4;105(17):1322-31.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA